A Retrospective Review of Chemotherapy for Patients with Small Bowel Adenocarcinoma in British Columbia.
A Retrospective Review of Chemotherapy for Patients with Small Bowel Adenocarcinoma in British Columbia.
复制标题
DOI：
10.7150/jca.16606
复制
发表时间：
2016
影响因子：
3.9
通讯作者：
Rao S
中科院分区：
文献类型：
--
作者：
Duerr D;Ellard S;Zhai Y;Taylor M;Rao S
背景：小肠腺癌（SBA）与不良预后相关。它是一种罕见的恶性肿瘤，因此很难研究。目前还没有随机的III期试验来指导最佳方法。不列颠哥伦比亚省癌症机构的省级癌症登记处包含SBA患者的长期数据。作者分析了1990年至2008年诊断的SBA患者的特征和治疗结果。材料与方法：回顾性分析150例经手术病理证实的SBA患者的临床资料。收集流行病学和治疗数据。采用Kaplan-Meier法估计无病生存期（DFS）和总生存期（OS）。结果如下：基线特征，如诊断时的中位年龄（64.5岁），肿瘤分期（I-II 33%，III-IV 58%，未知9%）和位置（十二指肠48%，空肠31%，回肠21%）与已发表的数据一致。55%的患者有癌症家族史。29例接受辅助化疗的患者的DFS和OS与47例未接受辅助化疗的患者无显著差异（分别为p = 1和p = 0.211）。在姑息治疗中，接受多种化疗的患者（21例患者）的OS在统计学上优于接受单药化疗的患者（12例患者）（p = 0.0228）。结论：我们的研究表明，晚期SBA患者接受多药化疗比单药化疗更有利于生存。然而，这是一项回顾性分析，有几个潜在的混杂因素。尽管如此，我们的研究增加了证据，表明化疗可能对SBA患者有益，至少在姑息治疗中是这样。
Background: Small bowel adenocarcinoma (SBA) is associated with a poor prognosis. It is an uncommon malignancy and therefore difficult to study. Randomized phase III trials are not available to guide best approaches. The Provincial Cancer Registry of the British Columbia Cancer Agency contains long-term data on patients with SBA. The authors analyzed characteristics and treatment outcomes for SBA patients diagnosed between 1990 and 2008. Material and methods: Charts of 150 patients with a histological diagnosis of SBA were retrospectively analyzed. Epidemiological and treatment data were collected. Disease-free survival (DFS) and overall survival (OS) were estimated by the Kaplan-Meier method. Results: Baseline characteristics, such as median age at diagnosis (64.5 years), tumor stage (I-II 33%, III-IV 58%, unknown 9%), and location (duodenum 48%, jejunum 31%, ileum 21%) were consistent with published data. 55% of patients had a positive family history of cancer. DFS and OS of 29 patients treated with adjuvant chemotherapy were not significantly different to that of 47 patients without (p = 1 and p = 0.211, respectively). In the palliative setting patients treated with polychemotherapy (21 patients) had statistically better OS than patients treated with monochemotherapy (12 patients) (p = 0.0228). Conclusions: Our study suggests a survival benefit for advanced-stage SBA patients treated with poly- versus monochemotherapy. This, however, was a retrospective analysis with several potential confounders. Nevertheless, our study adds to the evidence suggesting that chemotherapy may be beneficial for patients with SBA, at least in the palliative setting.
登录
查看更多内容
影响因子：
3.3
作者：
Chang, Hee-Kyung;Yu, Eunsil;Hong, Seung-Mo
通讯作者：
Hong, Seung-Mo
影响因子：
3.1
作者：
Overman, Michael J.;Kopetz, Scott;Wolff, Robert A.
通讯作者：
Wolff, Robert A.
影响因子：
6.2
作者：
Dabaja, BS;Suki, D;Ajani, J
通讯作者：
Ajani, J
皇家马斯登（Royal Marsden）的小肠腺癌的经验，该腺癌用长期的静脉输液5-氟尿嘧啶治疗。
影响因子：
8.8
作者：
Crawley, C;Ross, P;Norman, A;Hill, A;Cunningham, D
通讯作者：
Cunningham, D
影响因子：
6.2
作者：
Overman, Michael J.;Kopetz, Scoff;Wolff, Robert A.
通讯作者：
Wolff, Robert A.